CN115316669A - 一种营养素组合物 - Google Patents
一种营养素组合物 Download PDFInfo
- Publication number
- CN115316669A CN115316669A CN202110508902.6A CN202110508902A CN115316669A CN 115316669 A CN115316669 A CN 115316669A CN 202110508902 A CN202110508902 A CN 202110508902A CN 115316669 A CN115316669 A CN 115316669A
- Authority
- CN
- China
- Prior art keywords
- calcium
- vitamin
- group
- folic acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 235000015097 nutrients Nutrition 0.000 title abstract description 39
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 84
- 235000019152 folic acid Nutrition 0.000 claims abstract description 46
- 239000011724 folic acid Substances 0.000 claims abstract description 45
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229960000304 folic acid Drugs 0.000 claims abstract description 39
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 35
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000011575 calcium Substances 0.000 claims abstract description 28
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 28
- 235000001465 calcium Nutrition 0.000 claims abstract description 28
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 20
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 16
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 15
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 15
- 239000011710 vitamin D Substances 0.000 claims abstract description 15
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 15
- 229940046008 vitamin d Drugs 0.000 claims abstract description 15
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 12
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 12
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 12
- 239000011712 vitamin K Substances 0.000 claims abstract description 12
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 12
- 229940046010 vitamin k Drugs 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 41
- 229960005069 calcium Drugs 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 26
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 20
- 229960003563 calcium carbonate Drugs 0.000 claims description 20
- 235000010216 calcium carbonate Nutrition 0.000 claims description 20
- 208000006011 Stroke Diseases 0.000 claims description 14
- 229940014144 folate Drugs 0.000 claims description 6
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 235000008191 folinic acid Nutrition 0.000 claims description 4
- 239000011672 folinic acid Substances 0.000 claims description 4
- 229960001691 leucovorin Drugs 0.000 claims description 4
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 150000002224 folic acids Chemical class 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 229940105150 5-methyltetrahydrofolic acid Drugs 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 229960002713 calcium chloride Drugs 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- 229960004256 calcium citrate Drugs 0.000 claims description 2
- 229940092124 calcium citrate malate Drugs 0.000 claims description 2
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 claims description 2
- 239000004227 calcium gluconate Substances 0.000 claims description 2
- 235000013927 calcium gluconate Nutrition 0.000 claims description 2
- 229960004494 calcium gluconate Drugs 0.000 claims description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 229940095672 calcium sulfate Drugs 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 claims description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
- MPCMQXRREZMSPJ-UHFFFAOYSA-L calcium;2-hydroxybutanedioate;2-hydroxypropane-1,2,3-tricarboxylic acid;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].[O-]C(=O)C(O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MPCMQXRREZMSPJ-UHFFFAOYSA-L 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 229940065207 methylfolic acid Drugs 0.000 claims description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940068682 chewable tablet Drugs 0.000 claims 1
- 229960002061 ergocalciferol Drugs 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 235000001892 vitamin D2 Nutrition 0.000 claims 1
- 239000011653 vitamin D2 Substances 0.000 claims 1
- 235000005282 vitamin D3 Nutrition 0.000 claims 1
- 239000011647 vitamin D3 Substances 0.000 claims 1
- 229940021056 vitamin d3 Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 230000002195 synergetic effect Effects 0.000 abstract description 7
- 238000009098 adjuvant therapy Methods 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 description 45
- 229930003231 vitamin Natural products 0.000 description 45
- 235000013343 vitamin Nutrition 0.000 description 45
- 239000011782 vitamin Substances 0.000 description 45
- 241000700159 Rattus Species 0.000 description 43
- 150000003722 vitamin derivatives Chemical class 0.000 description 42
- 108090000573 Osteocalcin Proteins 0.000 description 16
- 102100031475 Osteocalcin Human genes 0.000 description 15
- 235000013399 edible fruits Nutrition 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 206010008118 cerebral infarction Diseases 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 8
- 206010008190 Cerebrovascular accident Diseases 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000010410 reperfusion Effects 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 230000037182 bone density Effects 0.000 description 6
- 230000002490 cerebral effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 230000007971 neurological deficit Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 244000099147 Ananas comosus Species 0.000 description 3
- 235000007119 Ananas comosus Nutrition 0.000 description 3
- 244000241257 Cucumis melo Species 0.000 description 3
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000016623 Fragaria vesca Nutrition 0.000 description 3
- 240000009088 Fragaria x ananassa Species 0.000 description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 2
- 244000298697 Actinidia deliciosa Species 0.000 description 2
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 235000004936 Bromus mango Nutrition 0.000 description 2
- 244000241235 Citrullus lanatus Species 0.000 description 2
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N Indigo Chemical compound N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 235000014826 Mangifera indica Nutrition 0.000 description 2
- 240000007228 Mangifera indica Species 0.000 description 2
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000009184 Spondias indica Nutrition 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 244000263375 Vanilla tahitensis Species 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WKZGKZQVLRQTCT-ABLWVSNPSA-N (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-formyloxy-5-oxopentanoic acid Chemical group N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(=O)OC=O)C(O)=O)C=C1 WKZGKZQVLRQTCT-ABLWVSNPSA-N 0.000 description 1
- LJYDIYITSYDTAY-LSBAASHUSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 LJYDIYITSYDTAY-LSBAASHUSA-N 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 241001409018 Anthracothorax viridis Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000006025 Durio zibethinus Nutrition 0.000 description 1
- 240000000716 Durio zibethinus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000000940 FEMA 2235 Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 235000007270 Gaultheria hispida Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000108452 Litchi chinensis Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000581835 Monodora junodii Species 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- 244000269152 Myrica pensylvanica Species 0.000 description 1
- 235000012851 Myrica pensylvanica Nutrition 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 244000288157 Passiflora edulis Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 241000287420 Pyrus x nivalis Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- KRPUUUJWTZKSOK-YDALLXLXSA-L calcium (4S)-4-[[4-[(2-amino-4-oxidopteridin-6-yl)methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical group [Ca++].Nc1nc([O-])c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC([O-])=O)C(O)=O)cnc2n1 KRPUUUJWTZKSOK-YDALLXLXSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- JMNIIIQOMSQWJN-ACGFUFEJSA-L calcium;(4s)-4-[[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical group [Ca+2].C1NC=2N=C(N)NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C1NC=2N=C(N)NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-ACGFUFEJSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000009627 gardenia yellow Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000005248 left atrial appendage Anatomy 0.000 description 1
- 235000007635 levomefolic acid Nutrition 0.000 description 1
- 239000011578 levomefolic acid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 108010034764 nitric acid reductase Proteins 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical group OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种营养素组合物，由维生素D、维生素K、叶酸类物质和钙组成。本发明提供的组合物具有预防或辅助治疗的作用，对中老年妇女骨质疏松或心脑血管疾病具有协同增效的作用。
Description
技术领域
本发明涉及一种营养素组合物，更准确地说，本发明涉及一种辅助中老年妇女预防骨质疏松或心脑血管疾病的维生素与矿物质组合物。本发明属于保健食品或药品领域。
背景技术
中老年人的骨质疏松问题十分常见。骨质疏松症(osteoporosis，OP)是一种全身性骨骼疾病，以骨矿物质减少、骨组织的微观结构退化为特征，这种病理改变使骨的脆性增加，骨折的危险性因而增加。随着社会人口的老龄化，该病的发病率日益上升，调查显示，我国40-49岁人群骨质疏松症患病率为3.2％，其中男性为2.2％，女性为4.3％；50岁以上人群骨质疏松患病率为19.2％，其中男性6.0％，女性为32.1％；65岁以上人群骨质疏松患病率达到32.0％，其中男性10.7％，女性51.6％(中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布.中华骨质疏松和骨矿盐疾病杂志，2019,12(4)；317-318)。
女性患者骨质疏松发生率明显高于男性患者，这与雌激素作用有关。雌激素水平足量时，不仅能促进磷盐和钙盐沉积，保持骨质正常，还能激活骨形成因子，从而避免骨质丢失。女性绝经后雌激素水平明显降低，对破骨的抑制作用减少，骨吸收功能增强，破骨作用大于成骨作用，骨量快速丢失，骨脆性增加，故绝经后女性较男性更易发生骨质疏松。骨质疏松可导致疼痛、骨折、骨骼变形等问题，严重影响老年人的健康和生活质量，髋部骨折作为骨质疏松的最严重后果，甚至可以引起患者死亡。
另一方面，中老年女性也是心脑血管病的高风险人群。氧化应激、糖尿病、高血压等传统心血管危险因子均与骨密度降低有关。从遗传因素看，冠心病和骨质疏松有7个共同相关的单核苷酸多态性变异。此外，老年妇女动脉钙化导致的炎症反应，不仅与脑卒中有关，也是导致骨质丢失、骨转换率改变及破骨活化的重要因素。因此，对于中老年女性而言，可能存在骨质疏松与心脑血管病共患的危险因素。
目前市场上营养素产品众多，但由于成分多、每种元素含量较低，缺乏针对性，消费者难以选择，实际保健效果尚难预料。因此，本发明旨在开发一种新的营养素组合物，指向性针对绝经后中老年妇女的骨骼与心脑血管健康问题，提供辅助干预手段，是对现有维生素产品的优化，符合精准营养的趋势。
发明内容
本发明的目的在于提供一种适用于中老年妇女精准营养的维生素与矿物质组合物，针对该人群易患骨质疏松及心脑血管疾病，提供一种具有预防或辅助治疗作用的营养素产品。
为了实现上述目的，本发明采用以下技术方案：
一种营养素组合物，包含以下成分组成：
(1)维生素D
(2)叶酸类物质
(3)维生素K
(4)钙
(5)保健食品可接受的辅料。
本发明所述的营养素组合物中，维生素D含量为2～100μg，优选2～20μg；所述叶酸类物质含量为300～2000μg，优选400～1200μg；所述维生素K含量为10～500μg，优选15～100μg；钙200～1500mg，优选1000-1300mg。
本发明所述的维生素D包括维生素D2和维生素D3，以及其他各组来源的各种维生素D形式。
本发明所述的叶酸类物质还包括5-甲基四氢叶酸(L-甲基叶酸)、亚叶酸、甲酰四氢叶酸、叶酸盐、叶酸或叶酸盐的活性代谢物和可在体内释放/生成叶酸的物质。
本发明所述维生素K包括植物来源的K1、微生物来源的K2，以及人工合成的K3和K4，优选植物来源的K1和微生物来源的K2。
本发明所述钙选自碳酸钙、醋酸钙、氯化钙、柠檬酸钙、葡萄糖酸钙、乳酸钙、磷酸氢钙、磷酸二氢钙、磷酸三钙、硫酸钙、L-乳酸钙、甘油磷酸钙、柠檬酸苹果酸钙。
本发明所述的营养素组合物可制成普通片剂、咀嚼片剂、软胶囊剂、硬胶囊剂、粉剂及颗粒剂等口服剂型。
本发明提供的组合物可以加入到药品、保健品、保健食品或功能食品等制剂形式中。
在本发明中，所述的可接受的辅料选自填充剂(分散剂)、助悬剂、润湿剂、粘合剂、崩解剂、润滑剂、矫味剂、稳定剂、包埋物、包衣预混剂、食用色素中的一种或几种组合。
其中，本发明所述的填充剂(分散剂)包括淀粉、可溶性淀粉、糊精、麦芽糊精、马铃薯淀粉、玉米淀粉、小麦淀粉、D-甘露糖醇、磷酸氢钙、无水磷酸氢钙、麦芽糖、木糖醇、山梨糖醇、微晶纤维素、异麦芽酮糖、乳粉、低取代羟丙纤维素、蔗糖、葡萄糖、乳糖、预胶化淀粉、食用植物油、聚乙二醇等的一种或几种。
本发明所述的助悬剂包括蜂蜡、虫蜡、卵磷脂、单硬脂酸甘油酯、乙基纤维素等其中的一种或几种，所述的润湿剂包括纯化水和乙醇，所述的粘合剂包括羟丙基甲基纤维素、聚维酮、羟丙纤维素、羧甲纤维素钠、淀粉、甲基纤维素、乙基纤维素、明胶、聚乙二醇、预胶化淀粉、蔗糖、葡萄糖等其中一种或几种。
本发明所述的崩解剂包括淀粉、羧甲淀粉钠、交联聚维酮、交联羧甲纤维素钠、低取代羟丙纤维素、碳酸氢钠与枸橼酸等其中的一种或几种，所述的润滑剂包括硬脂酸镁、硬脂酸、滑石粉、二氧化硅、氢化植物油、聚乙二醇、十二烷基硫酸钠、山嵛酸甘油酯、硬脂富马酸钠等其中的一种或几种。
本发明所述的矫味剂包括水果粉、食用香精、高倍甜味剂、酸味剂等其中的一种或几种，所述的水果粉包括橙粉、柠檬粉、樱桃粉、苹果粉、草莓粉、草莓粉、猕猴桃粉、橘粉、沙棘果粉、青梅果粉、芒果果粉、桑葚果粉、山楂果粉、西瓜果粉、菠萝果粉、蓝莓果粉、水蜜桃果粉、哈密瓜果粉、葡萄果粉、香草果粉、石榴果粉、玫瑰果粉等其中的一种或几种。
本发明所述的食用香精包括香草香精、甜橙香精、牛奶香精、苹果香精、葡萄香精、草莓香精、菠萝香精、水蜜桃香精、哈密瓜香精、柠檬香精、樱桃香精、甜玉米香精、香蕉香精、提子香精、葡萄香精、玫瑰香精、黑加仑香精、青苹果香精、芒果香精、青芒果香精、桔子香精、香橙香精、雪梨香精、草莓香精、青梅香精、蓝莓香精、杨梅香精、柚子香精、菠萝香精、番石榴香精、百香果香精、奇异果香精、樱桃香精、猕猴桃香精、西瓜香精、木瓜香精、哈密瓜香精、榴莲香精、荔枝香精、山楂香精、橄榄香精、桑葚香精等其中的一种或几种。
本发明所述的高倍甜味剂包括三氯蔗糖、阿斯巴甜、罗汉果甜苷、纽甜、甜菊苷，所述的酸味剂包括柠檬酸、柠檬酸、苹果酸、乳酸、酒石酸和富马酸，所述的食用色素包括焦糖色、栀子黄、姜黄色素和叶绿素、辣椒橙、辣椒红、葡萄皮红、胭脂红及其铝色淀、日落黄及其铝色淀、亮蓝及其铝色淀、靛蓝及其铝色淀、甜菜红、天然苋菜红、栀子蓝、植物炭黑、氧化铁黑、氧化铁红、黑豆红、喹啉黄、番茄红素、红曲红、黄氧化铁、可可壳色、红花黄、红曲黄色素等的一种或几种。
本发明所述的稳定剂包括维生素E、二丁基羟基甲苯(BHT)、丁基羟基茴香醚(BHA)、维生素C，所述的包埋物包括β-环糊精、α-环糊精、γ-环糊精、糊精、淀粉、食用变性淀粉、蔗糖、麦芽糊精、阿拉伯树胶等其中的一种或几种。
本发明根据中老年妇女易骨质疏松的特点，筛选功能协同的维生素和微量元素进行科学组方，通过补充最佳剂量维生素D、叶酸、维生素K和钙，协同治疗或预防中老年妇女骨质疏松症及心脑血管疾病。
在本发明中，心脑血管疾病是心脏血管和脑血管疾病的统称，泛指由于高脂血症、血液黏稠、动脉粥样硬化、高血压等所导致的心脏、大脑及全身组织发生的缺血性或出血性疾病。具体地，本发明中的心脑血管疾病包括不限于冠心病、心肌梗塞、脑卒中。
本发明提供的营养素组合物的另一优点是精准营养特性，精选有益于中老年妇女防治骨质疏松及心脑血管病的相关维生素(维生素D、K、叶酸)和矿物质(钙)，而非面面俱到的泛营养补充。
与现有产品相比，本发明所述的产品是一种具有协同效果、更精准的营养素组合物。下面结合实施例对本发明的实施方式作进一步描述，以下实施例中所列活性成分的量均以有效成分计。
具体实施方式
实施例1：营养素组合物对骨质疏松雌性大鼠的防治作用
动物：15月龄SD雌性大鼠，均自由饮食和饮水，适应性喂养1周。
方法：空白对照组、模型组、维生素KD叶酸1组(1+0.2+30ug/kg)、维生素KD叶酸2组(50+10+200ug/kg)、碳酸钙1组(以钙含量计20mg/kg)、碳酸钙2组(以钙含量计150mg/kg)、维生素KD钙1组(1+0.2+2*104ug/kg)、维生素KD钙2组(50+10+1.5*105ug/kg)、叶酸1组(30ug/kg)、叶酸2组(200ug/kg)、维生素KD1组(1+0.2ug/kg)、维生素KD2组(50+10ug/kg)、营养素1组(维生素K+维生素D+叶酸+碳酸钙，1ug/kg+0.2ug/kg+30ug/kg+20mg/kg)、营养素2组(维生素K+维生素D+叶酸+碳酸钙，50ug/kg+10ug/kg+200ug/kg+150mg/kg)，每组10只。除空白对照组外，其余大鼠均采取去卵巢法(参考《药理实验方法学》)制成骨质疏松模型。采用双能X线骨密度测量仪于造模后检测各组大鼠骨密度，以确定造模成功。各组大鼠给予对应药物干预，空白对照组和模型组大鼠给予生理盐水灌胃。
(1)全身骨密度检测。上述各组大鼠在药物干预12周后，禁食12h，10％水合氯醛腹腔注射麻醉后，采用双能X线骨密度测量仪检测，获得大鼠全身骨密度。
(2)血清骨代谢指标检测。取(1)检测后大鼠，心脏取血3mL，离心取上清液，-20度保存备用。按照试剂盒说明书运用酶联免疫吸附法检测大鼠血清骨生成代谢指标骨钙素(osteocalcin,BGP)及骨吸收代谢指标抗酒石酸磷酸酶(tartrate-resistantphosphatase,TRACP-5b),在450nm波长下测光密度(OD值)，计算血清BGP、TRAP-5b含量。
统计分析：试验数据采用GraphPad Prism 5统计分析软件进行统计处理；数据结果均以
表示。组间比较采用t检验，设定检验水准为α＝0.05，P<0.05有统计学差异，P>0.05无统计学差异。
协同系数：金正均Q值法又称概率相加法，根据在量效曲线区内，两种药物联用的药理作用及两种药物单用的药理作用，用如下公式计算Q＝EA+B/(EA+EB-EA×EB)(三种药物联用的药理作用及三种药物单用的药理作用，用如下计算公式计算：Q＝EA+B+C/(EA+EB+EC-EA*EB-EA*EC-EB*EC-EA*EB*EC))，式中分子代表“实测合并效应”，分母代表“期望合并效应”，Q为两者之比。Q值<0.85时认为两种药物联用为拮抗作用，0.85<Q值<1.15时认为是相加作用，Q值>1.15时认为是协同作用。为满足药理作用关系的分析，将实测值转化为可以直观体现药理作用强弱的效应，计算公式：Ei＝(1-Pi/P模型组)×100％，Pi为各组的实测值，P模型组为模型组的实测值。
结果：与空白对照组相比，模型组BMD明显下降，BGP明显升高，TRAP-5b明显升高，表明骨质疏松模型造模成功。
与模型组相比，维生素KD叶酸1组、碳酸钙1组、维生素KD钙1组、叶酸1组和维生素KD1组对BMD、BGP和TRAP-5b无显著影响；营养素1组能显著升高BMD、显著降低BGP和TRAP-5b，具有显著地统计学差异。
与模型组相比，维生素KD叶酸2组能显著升高BMD、显著降低BGP和TRAP-5b；碳酸钙2组能显著降低BGP和TRAP-5b；维生素KD钙2组能显著地升高BMD、显著降低BGP和TRAP-5b；维生素KD 2组和叶酸2组对上述三个检测指标无显著影响；营养素2组能非常显著地升高BMD、非常显著降低BGP和TRAP-5b，具有非常显著地统计学差异。
分析营养素1组与维生素KD叶酸1组、碳酸钙1组对骨质疏松大鼠BMD、BGP和TRAP-5b的Q值分别为1.02、1.21和1.33；分析营养素1组对维生素KD钙1组、叶酸1组对骨质疏松大鼠BMD、BGP和TRAP-5b的Q值均大于1.15(分别为1.46、2.15和1.82)；分析营养素1组对维生素KD 1组、碳酸钙1组和叶酸1组对骨质疏松大鼠BMD、BGP和TRAP-5b的Q值均大于1.15(分别为1.44、1.35和1.32)。
分析营养素2组与维生素KD叶酸2组、碳酸钙2组对骨质疏松大鼠BMD、BGP和TRAP-5b的Q值均大于1.15(分别为1.17、1.19和1.21)；营养素2组与维生素KD钙2组、叶酸2组对骨质疏松大鼠BMD、BGP和TRAP-5b的Q值均大于1.15(分别为2.26、1.70和1.41)；分析营养素2组对维生素KD 2组、碳酸钙2组和叶酸2组对骨质疏松大鼠BMD、BGP和TRAP-5b的Q值均大于1.15(分别为1.30、1.17和1.15)。
上述实验结果表明营养素1组和2组具有非常显著的防治骨质疏松的作用。通过分析组合物1组和2组与对应剂量的三联+单药或二联+单药+单药的协同系数，表明无论是在三联组合物加入一种单药还是二联组合物中加入两种单药成分，其防治骨质疏松的效果都产生协同作用。
表1.营养素组合物对骨质疏松大鼠的作用
注，与正常对照组相比，#P<0.05，##P<0.01；
实施例2.营养素组合物对脑卒中雌性大鼠的作用
动物：15月龄SD雌性大鼠，均自由饮食和进水适应性喂养1周。
方法：随机选取10只作为空白对照组；随机抽取10只作为模型组，余分组下：维生素KD叶酸1组(1+0.2+30ug/kg)、维生素KD叶酸2组(50+10+200ug/kg)、碳酸钙1组(以钙含量计20mg/kg)、碳酸钙2组(以钙含量计150mg/kg)、维生素KD钙1组(1+0.2+2*104ug/kg)、维生素KD钙2组(50+10+1.5*105ug/kg)、叶酸1组(30ug/kg)、叶酸2组(200ug/kg)、维生素KD1组(1+0.2ug/kg)、维生素KD2组(50+10ug/kg)、营养素1组(维生素K+维生素D+叶酸+碳酸钙，1ug/kg+0.2ug/kg+30ug/kg+20mg/kg)、营养素2组(维生素K+维生素D+叶酸+碳酸钙，50ug/kg+10ug/kg+200ug/kg+150mg/kg)，每组10只。维生素各组分别每日灌胃给予对应成分，空白对照组和模型组给予等量溶媒，一日一次，连续20周。
建模方法：
除正常对照组外，采用改良Zea-Longa法建立缺血性脑卒中大鼠模型。常规腹腔麻醉，仰卧位固定，常规备皮、消毒后于颈部正中做2cm切口，钝性分离颈部腺体组织，暴露并分离右侧颈总动脉、颈外动脉和颈内动脉，对颈外动脉主干进行游离、电凝，在距离颈总动脉分叉4mm位置结扎并离断，沿颈内动脉继续分离，暴露主干，将颈总动脉夹闭，颈外动脉残端做“V”型小口。经颈外动脉残端将线栓插入颈内动脉颅内段，直至颈总动脉分叉位置，结扎并将线栓尾端部分剪断，取出微动脉夹，消毒并逐层缝合。缺血2h后再灌注。采用改良Zea-Longa法评估，若为0分，则建模失败。若期间大鼠死亡或建模失败，则补给。
检测方法：
1)神经功能检测方法：
采用改良Zea-Longa法评价神经功能：将无神经功能缺损者记为0分；将瘫痪侧前爪不能完全伸展者记为1分，表示轻度神经功能缺损；将行走时大鼠向瘫痪侧转圈者记为2分，表示重度神经功能缺损；将行走时大鼠向瘫痪侧倾倒者记为3分，表示重度神经功能缺损；将不能自发行走且有意识丧失者记为4分，表示极重度神经功能缺损。
2)脑梗死面积检测方法
TTC染色法测定脑梗死面积：再灌注后迅速将大鼠断头处死，取新鲜脑组织，从额极开始连续切片，厚度3mm，共且5片，将其置于2％浓度的TTC中染色，37度孵育，15min后将其转入多聚甲醛固定，24h后用数码相机拍照，软件分析图像。
3)脑组织SOD活性及NO含量检测方法
将脑梗死区组织按照1:9比例降入冰冷的生理盐水，超声匀浆后离心，2000r/min，15min。二联喹啉酸法测定SOD蛋白含量，应用硝酸还原酶法按照试剂盒说明书测定NO含量。
统计分析：试验数据采用GraphPad Prism 5统计分析软件进行统计处理；数据结果均以
表示。组间比较采用t检验。
结果:15月龄大鼠接受20周溶媒或营养素组合物灌胃后，步入老年。由下表可见，模型组与正常对照组相比，神经功能评分明显升高，脑梗死面积显著增大，SOD、NO水平明显下降，表明缺血性脑卒中造模成功。
与模型组相比，营养素1组能显著降低神经功能评分、显著升高SOD和NO水平；维生素KD叶酸1组显著升高脑卒中大鼠SOD和NO水平，但对神经功能评分、脑梗死面积无显著影响；碳酸钙1组和维生素KD钙1组对上述指标无显著影响；叶酸1组显著升高脑卒中大鼠NO水平，但对SOD水平、神经功能评分和脑梗死面积无显著影响。
与模型组相比，营养素2组能显著降低神经功能评分、脑梗死面积、显著升高SOD和NO水平；维生素KD叶酸2组显著降低脑卒中大鼠神经功能评分、显著升高脑卒中大鼠SOD和NO水平，但对脑梗死面积无显著影响；叶酸2组显著升高SOD水平和NO水平，但对神经功能评分、脑梗死面积无显著影响；维生素KD钙2组和碳酸钙2组对上述指标无显著影响。
营养素1组对应维生素KD叶酸1组和碳酸钙1组对脑卒中大鼠的各项检测指标的Q值分别大于1.15(分别为2.66、1.92、1.16和1.23)；营养素1组对应维生素KD钙1组和叶酸1组对脑卒中大鼠的各项检测指标的Q值分别大于1.15(分别为2.45、3.27、1.62和1.27)。
营养素2组对应维生素KD叶酸2组和碳酸钙2组对脑卒中大鼠的各项检测指标的Q值分别大于1.15(分别为1.22、1.28、1.41和1.53)；营养素2组对应维生素KD钙2组和叶酸2组对脑卒中大鼠的各项检测指标的Q值分别大于1.15(分别为1.33、1.38、1.38和1.51)。
上述实验结果表明雌性大鼠灌服本发明提供的营养素组合物后，具有显著地改善脑卒中指标的效果。通过分析组合物1组和2组与对应剂量的三联+单药的协同系数，结果表明在三联组合物加入一种单药组成四种成分组合物后产生协同作用。
表2.营养素组合物对脑卒中大鼠的作用
注，与正常对照组相比，#P<0.05，##P<0.01；
实施例3.含不同叶酸成分的营养素组合物对心肌缺血再灌注磁性大鼠的作用
动物：15月龄SD雌性大鼠，均自由饮食和进水适应性喂养1周。
方法：随机选取10只作为空白对照组；随机抽取10只作为模型组，余下分组：维生素KD叶酸钙组(10ug/kg+1ug/kg+80ug/kg+130mg/kg)、维生素KD5-甲基四氢叶酸钙组(10ug/kg+1ug/kg+80ug/kg+130mg/kg)和维生素KD甲酰四氢叶酸钙组(10ug/kg+1ug/kg+80ug/kg+130mg/kg)。每组10只。维生素各组分别每日灌胃给予对应成分，空白对照组和模型组给予等量溶媒，一日一次，连续20周。末次给药后2h，参照造模方法，缺血45min，再灌注6h。
造模方法
大鼠麻醉后，行气管插管术。胸骨左缘第3肋间剪开皮肤及皮下组织，钝性分离肋间肌，打开胸腔，撑开3、4肋骨，打开胸膜和心包。在左心耳与肺动脉圆锥之间，找到与心大静脉走向一致行于心肌内的、隐约可见线状乳白色冠脉。高位冠脉结扎处放一长约0.5mm直径为1.5mm软棉线，用6.0丝线结扎。进针深度为1-1.5mm、宽2-3mm，同时避免过多触及心肌和刺破左肺叶。再灌注时由棉线处剪断结扎线。
检测方法：
实验完毕迅速取出大鼠心脏，切取心肌的缺血再灌注损伤区组织0.1g，按1:10的比例加入0.9％氯化钠溶液，采用玻璃研磨器制成匀浆，离心取上清液-20度保存。MDA含量采用TBA法测定，GSH-PX含量采用比色法测定。
再灌注6h后从大鼠腹主动脉取血，离心，取上清液采用ELISA法测定可溶性血管细胞粘附分子-1(sVCAM-1)。
统计分析：试验数据采用GraphPad Prism 5统计分析软件进行统计处理；数据结果均以
表示。组间比较采用t检验。
结果：
相对于正常对照组，模型组大鼠sVCAM-1、MDA水平显著升高，GSH-PX水平显著降低，具有统计学差异，表明造模成功。
相对于模型组，各组营养素组合物均能显著升高心肌缺血再灌注雌性大鼠的GSH-PX水平、显著降低sVCAM-1、MDA水平，但维生素KD5-甲基四氢叶酸钙组对上述三个检测指标的作用更加显著，表明5-甲基四氢叶酸与维生素KD钙组合后效果更为显著。
表3营养素组合物对心肌缺血再灌注雌性大鼠的作用(X±SD，n＝10)
注：模型组比较，#P<0.05，##P<0.01
Claims (10)
1.一种组合物，由以下成份组成：
(1)2～100μg维生素D，
(2)10～500μg维生素K，
(3)30～2000μg叶酸类物质，
(4)200～1500mg钙，
(5)保健食品或药品可接受的辅料。
2.根据权利要求1所述的组合物，其特征在于：所述维生素D含量为2～20μg，所述叶酸含量为40～1200μg，所述维生素K含量为15～100μg，所述钙含量为1000-1300mg。
3.根据权利要求1～2任一项所述的组合物，其特征在于：所述的维生素D是维生素D2、D3或其他各组来源的各种维生素D形式。
4.根据权利要求1～2任一项所述的组合物，其特征在于：所述的叶酸类物质还包括5-甲基四氢叶酸(L-甲基叶酸)、亚叶酸、甲酰四氢叶酸、、叶酸盐、叶酸或叶酸盐的活性代谢物和可在体内释放/生成叶酸的物质。
5.根据权利要求1～2任一项所述的组合物，其特征在于：所述的维生素K包括植物来源的K1、微生物来源的K2和人工合成的K3和K4。
6.根据权利要求1～2任一项所述的组合物，其特征在于：所述的钙选自碳酸钙、醋酸钙、氯化钙、柠檬酸钙、葡萄糖酸钙、乳酸钙、磷酸氢钙、磷酸二氢钙、磷酸三钙、硫酸钙、L-乳酸钙、甘油磷酸钙、柠檬酸苹果酸钙。
7.根据权利要求1所述的组合物，其特征在于：所述的保健食品可制成普通片剂、咀嚼片剂、软胶囊剂、硬胶囊剂、粉剂及颗粒剂。
8.权利要求1～7任一项所述的组合物在制备用于预防或辅助治疗中老年妇女骨质疏松症的制品中的用途。
9.权利要求1～7任一项所述的组合物在制备用于预防或辅助治疗中老年妇女心脑血管疾病的制品中的用途。
10.根据权利要求9所述的用途,其特征在于:所述的心脑血管疾病是冠心病、心肌梗塞、脑卒中。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110508902.6A CN115316669A (zh) | 2021-05-11 | 2021-05-11 | 一种营养素组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110508902.6A CN115316669A (zh) | 2021-05-11 | 2021-05-11 | 一种营养素组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115316669A true CN115316669A (zh) | 2022-11-11 |
Family
ID=83912554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110508902.6A Pending CN115316669A (zh) | 2021-05-11 | 2021-05-11 | 一种营养素组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115316669A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634130A (zh) * | 2004-11-05 | 2005-07-06 | 曾繁玉 | 防治妇女绝经后骨质疏松组合物 |
| CN103142640A (zh) * | 2013-04-01 | 2013-06-12 | 李拖平 | 含有维生素k2的具有预防与治疗骨质疏松症的保健品 |
| CN106901379A (zh) * | 2017-03-11 | 2017-06-30 | 深圳泰乐德营养与健康有限公司 | 一种辅助预防心血管疾病的维生素保健食品 |
| CN107232611A (zh) * | 2017-05-22 | 2017-10-10 | 深圳泰乐德营养与健康有限公司 | 一种由维生素d、k和叶酸组成的营养素组合物 |
| CN110338424A (zh) * | 2018-04-08 | 2019-10-18 | 北京奥萨医药研究中心有限公司 | 一种适用于中老年人的保健食品 |
-
2021
- 2021-05-11 CN CN202110508902.6A patent/CN115316669A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634130A (zh) * | 2004-11-05 | 2005-07-06 | 曾繁玉 | 防治妇女绝经后骨质疏松组合物 |
| CN103142640A (zh) * | 2013-04-01 | 2013-06-12 | 李拖平 | 含有维生素k2的具有预防与治疗骨质疏松症的保健品 |
| CN106901379A (zh) * | 2017-03-11 | 2017-06-30 | 深圳泰乐德营养与健康有限公司 | 一种辅助预防心血管疾病的维生素保健食品 |
| CN107232611A (zh) * | 2017-05-22 | 2017-10-10 | 深圳泰乐德营养与健康有限公司 | 一种由维生素d、k和叶酸组成的营养素组合物 |
| CN110338424A (zh) * | 2018-04-08 | 2019-10-18 | 北京奥萨医药研究中心有限公司 | 一种适用于中老年人的保健食品 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11219590B2 (en) | Anti-aging agent and anti-aging method | |
| ES2220102T3 (es) | Formulaciones de soja y su uso para mejorar la salud. | |
| US10111925B2 (en) | Formulations comprising plant extracts | |
| US20200268827A1 (en) | Composition for prevention, improvement or treatment of osteoarthritis comprising alpinia oxyphylla extract as effective component | |
| CN107028191B (zh) | 一种适合中老年人群精准营养的维生素组合物 | |
| KR101189108B1 (ko) | 황칠나무 추출물을 포함하는 남성 성기능 개선용 조성물 | |
| WO2004112510A1 (ja) | 運動生理機能向上剤 | |
| CN115316669A (zh) | 一种营养素组合物 | |
| KR20190017860A (ko) | 고삼 추출물 또는 마트린을 포함하는 진정 또는 수면유도용 조성물 | |
| KR101237215B1 (ko) | 장염 예방 또는 치료용 약학 조성물 | |
| TWI437998B (zh) | 大葉冬青提取物之用途 | |
| CN110604308A (zh) | 一种具有镇痛作用的营养组合物 | |
| US20040151769A1 (en) | Film coated tablet containing an extract of red vine leaves | |
| CN106946866A (zh) | 一种预防和治疗脑卒中的药物及其制备方法 | |
| CN107156816B (zh) | 一种适用于早期糖尿病人群和代谢综合征人群的保健食品 | |
| MXPA01000973A (es) | Un nuevo agente analgesico antiinflamatorio y de cicatrizacion de heridas. | |
| JP6840647B2 (ja) | 液体組成物、その白濁改善剤、臭気改善剤、及び製造方法 | |
| CN112807321B (zh) | 治疗脑缺血再灌注损伤的组合物及其应用 | |
| KR100597564B1 (ko) | 골성장 촉진활성을 갖는 엘루테로사이드 ｅ를 함유하는약학조성물 | |
| BRPI0317883B1 (pt) | comprimido revestido com filme compreendendo um extrato de folhas de vinha vermelha | |
| CN106727605B (zh) | 环维黄杨星d在制备预防或治疗缺血性脑卒中药物中的应用 | |
| RU2819538C1 (ru) | Рецептура БАД специализированного спортивного питания для восстановления, включающего профилактику артритов и других заболеваний суставов, и включения в программу анти-эйдж терапии | |
| KR20050104091A (ko) | 골성장촉진활성을 갖는 엘루테로사이드 이 및 이를함유하는 기능성 식품 및 약학적 제제 | |
| US20230404945A1 (en) | Application of alpha-asarone in preparation of medicine for preventing or treating hemorrhagic stroke | |
| KR101113978B1 (ko) | 원지 추출물을 유효성분으로 함유하는 발기부전 예방 및 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |